{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:33:02Z","timestamp":1792128782831,"version":"4.4.0"},"reference-count":61,"publisher":"Informa UK Limited","issue":"26","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.2217\/fon-2022-0450","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T11:39:11Z","timestamp":1658230751000},"page":"2879-2889","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia"],"prefix":"10.1080","volume":"18","author":[{"given":"Vladimir","family":"Ivanov","sequence":"first","affiliation":[{"name":"Almazov National Medical Research Centre, Saint Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Peng","family":"Yeh","sequence":"additional","affiliation":[{"name":"China Medical University Hospital, Taichung City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[{"name":"Fakultni Nemocnice Brno & Masaryk University, Brno, Czechia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Saini","sequence":"additional","affiliation":[{"name":"London Health Sciences Center, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Unal","sequence":"additional","affiliation":[{"name":"Erciyes University Medical School, Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boyiadzis","sequence":"additional","affiliation":[{"name":"Genentech Inc., San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Hoffman","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingston","family":"Kang","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiya N","family":"Addo","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wellington L","family":"Mendes","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T","family":"Fathi","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300874"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S135013"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.619085"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1302"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1558"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00148-9"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-772368"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0472"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4073"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-337725"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.8329"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9429"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-246470"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.872"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-674127"},{"key":"e_1_3_7_22_1","unstructured":"U.S. Food and Drug Administration . FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia 2020.www.fda.gov\/drugs\/resourcesinformation-approved-drugs\/fda-approves-onureg-azacitidine-tablets-acute-myeloid-leukemia"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.326"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004444"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0313"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01600"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33477"},{"issue":"2","key":"e_1_3_7_29_1","first-page":"135","article-title":"The American Cancer Society\u2019s Facts & Figures: 2020 Edition","volume":"11","author":"Viale PH","year":"2020","unstructured":"Viale PH . The American Cancer Society\u2019s Facts & Figures: 2020 Edition. J. Adv. Pract. Oncol.11(2), 135\u2013136 (2020).","journal-title":"J. Adv. Pract. Oncol."},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1875814"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311402"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.813"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901409"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00765-5"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_7_38_1","unstructured":"US FDA. FDA approves venetoclax in combination for AML in adults. www.fda.gov\/drugs\/fda-approves-venetoclax-combination-aml-adults"},{"key":"e_1_3_7_39_1","unstructured":"US FDA. FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia. www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004856"},{"key":"e_1_3_7_41_1","unstructured":"US FDA. FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia. www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01546"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.2307\/2530286"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2012.12.013"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4642"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1039\/c0ib00144a"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-791350"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1420474"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-019-0133-1"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1900"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3057"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0233-1"},{"key":"e_1_3_7_56_1","unstructured":"ClinicalTrials.gov . A study of ASP2215 (Gilteritinib) administered as maintenance therapy following induction\/consolidation therapy for subjects with FMS-like tyrosine kinase 3 (FLT3\/ITD) acute myeloid leukemia (AML) in first complete remission (NCT02927262). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02927262"},{"key":"e_1_3_7_57_1","unstructured":"ClinicalTrials.gov. Study of MLN9708 as maintenance therapy for patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) in remission (NCT02302846). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02302846"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7075"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036715"},{"key":"e_1_3_7_60_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S187409"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.07.015"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403289"},{"key":"e_1_3_7_63_1","unstructured":"ClinicalTrials.gov. A study of oral venetoclax tablets and oral azacitidine versus oral azacitidine as maintenance therapy in adult participants with acute myeloid leukemia in first remission after conventional chemotherapy (VIALE-M). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04102020?term=VIALE-M"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:18Z","timestamp":1719125178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":61,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.2217\/fon-2022-0450"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0450","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}